Squarepoint Ops LLC Raises Holdings in Haemonetics Corporation $HAE

Squarepoint Ops LLC boosted its stake in Haemonetics Corporation (NYSE:HAE) by 194.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,124 shares of the medical instruments supplier’s stock after purchasing an additional 56,843 shares during the period. Squarepoint Ops LLC’s holdings in Haemonetics were worth $6,459,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. California State Teachers Retirement System boosted its stake in shares of Haemonetics by 7,550.6% during the second quarter. California State Teachers Retirement System now owns 4,024,650 shares of the medical instruments supplier’s stock valued at $301,849,000 after purchasing an additional 3,972,044 shares during the period. AQR Capital Management LLC increased its stake in shares of Haemonetics by 48.6% in the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after buying an additional 1,034,226 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Haemonetics by 994.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after buying an additional 1,254,035 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares during the last quarter. Finally, North Peak Capital Management LLC boosted its position in Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after buying an additional 740,626 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HAE. Citigroup boosted their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. BTIG Research raised their target price on Haemonetics from $96.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Finally, Robert W. Baird upped their price target on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.78.

Haemonetics Price Performance

HAE opened at $101.31 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The company has a market cap of $4.61 billion, a price-to-earnings ratio of 49.66, a price-to-earnings-growth ratio of 2.07 and a beta of 0.54. The stock has a fifty day simple moving average of $89.90 and a two-hundred day simple moving average of $72.81. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $109.57.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.10 EPS. Research analysts predict that Haemonetics Corporation will post 5.29 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.